ACTH-ectopic syndrome in patient with lung carcinoid
https://doi.org/10.14341/2071-8713-5246
Abstract
About the Authors
L DzeranovaD Mikhailova
LYa Rozhinskaya
E Pigarova
A Vorontsov
O Manchenko
E Pekareva
N Kuznetsov
D Bel'tsevich
I Kim
N Urazovsky
References
1. Эндокринология. Национальное руководство. Под ред. И.И. Дедова, Г.А.. Мельниченко. - М.: ГЭОТАР-Медиа, 2008 г. - С. 662-672.
2. Эндокринология. Национальное руководство. Под ред. И.И. Дедова, Г.А.. Мельниченко. - М.: ГЭОТАР-Медиа, 2008 г. - С. 694-702.
3. Granberg D., Wilander E., Oberg К. et al. Prognostic markers in patients with typical bronchial carcinoid tumors. J. Clin. Endocrinol. Metab. - 2000; 85:3425-3430.
4. Hofland L.J., Lamberts S.W.J. Somatostatin receptor subtype expression in human tumors. Ann. Oncol. - 2001. - Vol. 12, (Suppl. 2). - P. 31 -36.
5. Irvin M. Modlin, Kjell Oberg et al: A century of advances in neuroendocrine tumor biology and treatment. Published by Felsenstein СССР. IBSN 987-3-00-023638-9. P: 4-22; 40-148; 304-446. 2007.
6. Kelsen D.G., Cheng E., Kemeny N. et al. Streptozotocin and Adriamycin in the treatment of APUD tumors (carcinoid islet cell and medullary thyroid) // Proc. Amer. Assoc. Cancer. Res. - 1982. - Vol. 23. - P. 433.
7. Limper A.H., Carpenter P.C, Scheithauer B. et al. The Cushing syndrome induced by bronchial carcinoid tumors//Ann. Intern. Med., 1992.117:209-214.
8. Travis W.D., Rush W., Flieder D.B. et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid //Am. J. Surg. Pathol. 1998. 22: 934-944.
9. Vaidya В., Richardson D., Hilton C.J. et al. Adrenocorticotropin-secreting carcinoid tumour identified and treated 12 years after presentation with Cushing's syndrome // Postgrad. Med. J. - 1997, Nov.;73(865): 737-9.
Review
For citations:
, , , , , , , , , , ACTH-ectopic syndrome in patient with lung carcinoid. Obesity and metabolism. 2009;6(3):54-58. (In Russ.) https://doi.org/10.14341/2071-8713-5246

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).